Latest Regulatory News

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Magnis Energy Technologies progresses detailed engineering on its Nachu Graphite Project and moves to fast track US anode material production, while navigating ASX suspension and IM3NY bankruptcy fallout.

Codeifai Limited has raised $2.35 million through a share placement to fund key acquisitions and expand its footprint in quantum computing and AI. The move signals a strategic push towards U.S. market engagement and commercialisation of cutting-edge technology.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

CAQ Holdings reported a significant 35% decline in leasing revenue for the June 2025 quarter amid tenant contract changes and high vacancy rates. The company is optimistic about a turnaround following new customs policies in Hainan Free Trade Port set to take effect in December.

Latrobe Magnesium secures EPA licence extension and prepares to start magnesium oxide production in August, while pursuing a significant legal counterclaim and advancing commercial plant plans.

Dateline Resources advances its Colosseum Gold-REE Project with a robust feasibility study, expanded exploration, and strong US government support, positioning itself as a key player in critical minerals.

PointsBet Holdings has secured interim orders from the Takeovers Panel to restrain betr Entertainment from dispatching its takeover bidder’s statement, intensifying the high-stakes contest for control.

The Star Entertainment Group reported steady Q4 FY25 revenue of $270 million but widened its EBITDA loss to $27 million, reflecting ongoing regulatory pressures and operational challenges. The company secured $233 million from strategic investors Bally’s Corporation and Investment Holdings, while negotiations continue over its Brisbane joint venture exit.

Forrestania Resources has voluntarily suspended trading on the ASX as it prepares to announce a significant acquisition, signaling a potentially transformative move for the mining company.

Vital Metals Limited has released a comprehensive Scoping Study for its Tardiff Rare Earths deposit in Canada, revealing strong economic potential with an 11-year mine life and significant neodymium-praseodymium resources.